Thyrocare Technologies Ltd
NSE:THYROCARE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
559.95
985.8
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Thyrocare Technologies Ltd
Net Income (Common)
Thyrocare Technologies Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
Net Income (Common)
â‚ą776.4m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
||
Dr Agarwal's Eye Hospital Ltd
BSE:526783
|
Net Income (Common)
â‚ą489.3m
|
CAGR 3-Years
108%
|
CAGR 5-Years
34%
|
CAGR 10-Years
32%
|
||
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
Net Income (Common)
â‚ą4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
||
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
|
Net Income (Common)
â‚ą1.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
||
Krsnaa Diagnostics Ltd
NSE:KRSNAA
|
Net Income (Common)
â‚ą568.4m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
Net Income (Common)
â‚ą1.4B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
Thyrocare Technologies Ltd
Glance View
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.
See Also
What is Thyrocare Technologies Ltd's Net Income (Common)?
Net Income (Common)
776.4m
INR
Based on the financial report for Jun 30, 2024, Thyrocare Technologies Ltd's Net Income (Common) amounts to 776.4m INR.
What is Thyrocare Technologies Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-3%
Over the last year, the Net Income (Common) growth was 30%. The average annual Net Income (Common) growth rates for Thyrocare Technologies Ltd have been -23% over the past three years , -3% over the past five years .